A National Taiwan University Hospital (NTUH) research team has become the first to develop a noninvasive urinary biomarker to monitor those recovering from thyroid cancer and potentially predict the risk of recurrence, the hospital said yesterday.
NTUH Department of Internal Medicine deputy director Wang Chih-yuan (王治元), who led the research team, said thyroid cancer is among the 10 most common cancers in Taiwan and the most common in the endocrine system, with about 5,000 new cases diagnosed each year.
About 80 percent of all thyroid cancer cases are papillary thyroid carcinoma, which tends to grow slowly and has a relatively good prognosis if treated appropriately, while other types of thyroid cancer include follicular carcinoma, medullary carcinoma and anaplastic carcinoma, Wang said.
Photo: CNA
As people with papillary thyroid cancer have relatively high survival rates of 20 to 30 years after treatment, developing an effective lifelong follow-up biomarker for early detection of a recurrence is important, he said.
Many people undergo a thyroidectomy to remove a portion or the entire thyroid gland, which is combined with radioactive iodine therapy, but the recurrence rate after surgery is 10 to 28 percent, he said.
In common clinical practice, follow-up treatment involves periodically measuring a person’s thyroglobulin levels in their blood to detect any remaining cancer cells and monitor for recurrence, Wang said.
However, the thyroglobulin antibody can interfere with the blood test result, and a recombinant human thyrotropin stimulation might be needed to increase the test’s sensitivity, but that is costly — about NT$40,000 per test, he said.
In the past several years, Wang’s research team analyzed urinary exosomal proteins, and found that the urinary exosomal thyroglobulin could be used as a biological marker to substitute serum thyroglobulin, as it is more sensitive and accurate, and is not affected by the thyroglobulin antibody.
Exosomes are nanovesicles secreted into extracellular environments, including plasma, saliva, urine and other body fluids, and can carry nucleic acids, proteins and lipids that are unique to the origin cell, the team’s paper said.
Studies have indicated that exosomes hold promise in the diagnosis of thyroid diseases, it said.
The research team collected urine samples from people diagnosed with papillary thyroid carcinoma and follicular carcinoma, from pre-surgery, post-surgery, and at three and six months after their surgery for analysis, Wang said.
They found a significant correlation between urinary exosomal thyroglobulin concentration and tumor size and the anatomic stage of the person’s cancer, he said.
The findings suggest that urinary exosomal thyroglobulin could be useful for predicting the risk of thyroid cancer recurrence, he said.
A urine test is noninvasive and could potentially detect cancer recurrence three to five years earlier than through a thyroglobulin blood test, he added.
“Our study not only provides thyroid cancer patients a more sensitive post-surgery tracking method, it can also hopefully reduce their financial burden and mental stress,” Wang said.
The team’s latest finding was published in May in the International Journal of Nanomedicine.
The biomarker the team developed has received patent approval in Japan, the US and Taiwan, the hospital said.
Seven of the 17 NT$10 million (US$311,604) winning receipts from the November-December uniform invoice lottery remain unclaimed as of today, the Ministry of Finance said, urging winners to redeem their prizes by May 5. The reminder comes ahead of the release of the winning numbers for the January-February lottery tomorrow. Among the unclaimed receipts was one for a NT$173 phone bill in Keelung, while others were for a NT$5,913 purchase at Costco in Taipei's Neihu District (內湖), a NT$49 purchase at a FamilyMart in New Taipei City's Tamsui District (淡水), and a NT$500 purchase at a tea shop in New Taipei City's
Taiwanese officials were shown the first of 66 F-16V fighter jets purchased by Taiwan from the United States, the Ministry of National Defense said yesterday, adding the aircraft has completed an initial flight test and is expected to be delivered later this year. A delegation led by Deputy Minister of National Defense Hsu Szu-chien (徐斯儉) visited Lockheed Martin’s F-16 C/D Block 70 (also known as F-16V) assembly line in South Carolina on March 16 to view the aircraft. The jet will undergo a final acceptance flight in the US before being delivered to Taiwan, the
The New Taipei Metro's Sanyin Line and the eastern extension of the Taipei Metro's Tamsui-Xinyi Line (Red Line) are scheduled to begin operations in June, the National Development Council said today. The Red Line, which terminates at Xiangshan Station, would be connected by the 1.4km extension to a new eastern terminal, Guangci/Fengtian Temple Station, while the Sanyin Line would link New Taipei City's Tucheng and Yingge stations via Sanxia District (三峽). The council gave the updates at a council meeting reviewing progress on public construction projects for this year. Taiwan's annual public infrastructure budget would remain at NT$800 billion (US$25.08 billion), with NT$97.3
Deliveries of delayed F-16V jets are expected to begin in September, Minister of National Defense Wellington Koo (顧立雄) said today, after senior defense officials visited the US last week. The US in 2019 approved a US$8 billion sale of Lockheed Martin F-16 jets to Taiwan, a deal that would take the nation’s F-16 fleet to more than 200 jets, but the project has been hit by issues including software problems. Koo appeared today before a meeting of the legislature’s Foreign Affairs and National Defense Committee, which is discussing different versions of the special defense budget this week. The committee is questioning officials today,
RSS